Alnylam Pharmaceuticals (ALNY) Announces New RNAi Therapeutic Program For The Treatment Of Hepatitis B Virus (HBV) Infection And Reports An Up To 2.3 Log10 Reduction Of HBV Surface Antigen (HBsAg) In Chronically Infected Chimpanzees
5/12/2014 8:53:18 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has named a new program to its pipeline: ALN-HBV for the treatment of hepatitis B virus (HBV) infection. The new ALN-HBV program derives from the company’s January 2014 acquisition of Merck’s RNAi assets, including their Sirna Therapeutics subsidiary. HBV infection afflicts 400 million people worldwide, with 1 to 2 million people in the U.S., and is a leading cause of liver disease and hepatocellular carcinoma (HCC) worldwide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by